Cancer Network
Cancer Network, along with the peer-reviewed journal ONCOLOGY, offers healthcare professionals valuable insights and expert opinions on topics related to cancer. This includes information on screening, early detection, diagnosis, treatment options, and prevention strategies for various types of cancer.
Outlet metrics
Global
#343294
United States
#116496
Health/Health
#2376
Articles
-
1 day ago |
cancernetwork.com | Russ Conroy
Administering tislelizumab-jsgr (Tevimbra) as monotherapy or in combination with other agents significantly prolonged progression-free survival (PFS) and overall survival (OS) across different lung cancer populations, according to findings from a systematic review and meta-analysis published in Cureus.1Across 4 phase 3 studies, treatment with tislelizumab significantly improved OS vs control therapy, with no heterogeneity noted across trials (HR, 0.72; 95% CI, 0.63-0.81).
-
1 day ago |
cancernetwork.com | Russ Conroy
Tumor treating fields (TTFields; Optune Lua) in combination with immune checkpoint inhibitors (ICIs) or docetaxel has received the Conformité Européenne (CE) Mark approval as a therapy for patients with metastatic non–small cell lung cancer (NSCLC) who have progressed on or after a platinum-containing regimen, according to a press release from the developers, Novocure.1 Developers have launched the local registration requirements for TTFields in Germany and are anticipating that the therapy...
-
2 days ago |
cancernetwork.com | Russ Conroy
Treatment with nadofaragene firadenovec-vncg (Adstiladrin) elicited a strong complete responses (CR) rate in a small cohort of patients with high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors, according to a press release on findings from a Japanese phase 3 trial.1 Findings presented at the 112th Annual Meeting of the Japanese Urological Association demonstrated a CR rate of 75% (n =...
-
3 days ago |
cancernetwork.com | Russ Conroy
The number of prior lines of therapy did not influence how patients with multiple myeloma locally responded to radiotherapy, according to findings from a retrospective study published in Advances in Radiation Oncology.1Six-month local responses were evaluable for 217 lesions; 13.4% (n = 29) showed complete responses (CRs), 65% (n = 141) showed partial responses (PRs), 19.4% (n = 42) exhibited stable disease, and 2.3% (n = 5) demonstrated progressive disease.
-
4 days ago |
cancernetwork.com | Russ Conroy
Hyper-fractionated twice-daily radiotherapy conferred an overall survival (OS) improvement vs standard-dose radiation without increasing toxicity among patients with limited-stage small cell lung cancer (LS-SCLC), according to findings from a phase 3 study (NCT03214003) published in Lancet Respiratory Medicine.1 After a median follow-up of 46 months (IQR, 33-56) across the entire study population, the median OS was 60.7 months (95% CI, 49.2-62.0) with 54 Gy of radiation vs 39.5 months (95%...
Cancer Network journalists
Contact details
Address
123 Example Street
City, Country 12345
Email Patterns
Contact Forms
Contact Form
Website
https://cancernetwork.com/Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →